619 related articles for article (PubMed ID: 19130322)
1. Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor.
Linderholm B; Bergqvist J; Hellborg H; Johansson U; Linderholm M; von Schoultz E; Elmberger G; Skoog L; Bergh J
Med Oncol; 2009 Dec; 26(4):480-90. PubMed ID: 19130322
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor receptor 2 and downstream p38 mitogen-activated protein kinase are possible candidate markers of intrinsic resistance to adjuvant endocrine treatment in steroid receptor positive breast cancer.
Linderholm BK; Hellborg H; Johansson U; Skoog L; Lehtiö J
Breast Cancer Res Treat; 2011 Jan; 125(2):457-65. PubMed ID: 21110084
[TBL] [Abstract][Full Text] [Related]
4. Prognostic role of human epidermal growth factor receptor 2 status in premenopausal early breast cancer treated with adjuvant tamoxifen.
Meattini I; Livi L; Saieva C; Franceschini D; Scotti V; Mangoni M; Loi M; Di Brina L; Zei G; Bonomo P; Greto D; Gelain E; Nori J; Sanchez LJ; Orzalesi L; Bianchi S; Biti G
Clin Breast Cancer; 2013 Aug; 13(4):247-53. PubMed ID: 23684167
[TBL] [Abstract][Full Text] [Related]
5. Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.
Ulas A; Kos T; Avci N; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
Asian Pac J Cancer Prev; 2015; 16(4):1643-9. PubMed ID: 25743846
[TBL] [Abstract][Full Text] [Related]
6. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status.
Dowsett M; Houghton J; Iden C; Salter J; Farndon J; A'Hern R; Sainsbury R; Baum M
Ann Oncol; 2006 May; 17(5):818-26. PubMed ID: 16497822
[TBL] [Abstract][Full Text] [Related]
7. Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF.
Sanchez BC; Sundqvist M; Fohlin H; Spyratos F; Nordenskjöld B; Stål O; Linderholm BK
Eur J Cancer; 2010 Jun; 46(9):1580-7. PubMed ID: 20413297
[TBL] [Abstract][Full Text] [Related]
8. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
Regan MM; Pagani O; Francis PA; Fleming GF; Walley BA; Kammler R; Dell'Orto P; Russo L; Szőke J; Doimi F; Villani L; Pizzolitto S; Öhlschlegel C; Sessa F; Peg Cámara V; Rodríguez Peralto JL; MacGrogan G; Colleoni M; Goldhirsch A; Price KN; Coates AS; Gelber RD; Viale G;
Breast Cancer Res Treat; 2015 Nov; 154(2):275-86. PubMed ID: 26493064
[TBL] [Abstract][Full Text] [Related]
9. Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer.
Yu KD; Jiang YZ; Hao S; Shao ZM
BMC Med; 2015 Oct; 13():254. PubMed ID: 26437901
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer.
Fan Y; Ding X; Xu B; Ma F; Yuan P; Wang J; Zhang P; Li Q; Luo Y
Medicine (Baltimore); 2015 Nov; 94(46):e2066. PubMed ID: 26579819
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study.
Vaz-Luis I; Seah D; Olson EM; Wagle N; Metzger-Filho O; Sohl J; Litsas G; Burstein HJ; Krop IE; Winer EP; Lin NU
Clin Breast Cancer; 2013 Aug; 13(4):254-63. PubMed ID: 23829891
[TBL] [Abstract][Full Text] [Related]
12. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
[TBL] [Abstract][Full Text] [Related]
13. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
[TBL] [Abstract][Full Text] [Related]
14. The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.
Linardou H; Kalogeras KT; Kronenwett R; Kouvatseas G; Wirtz RM; Zagouri F; Gogas H; Christodoulou C; Koutras AK; Samantas E; Pectasides D; Bafaloukos D; Fountzilas G
Breast Cancer Res; 2012 Nov; 14(6):R145. PubMed ID: 23146280
[TBL] [Abstract][Full Text] [Related]
15. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
Rydén L; Jirström K; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Thorstenson S; Jönsson PE; Landberg G
J Clin Oncol; 2005 Jul; 23(21):4695-704. PubMed ID: 16034044
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study.
Kawaguchi H; Masuda N; Nakayama T; Aogi K; Anan K; Ito Y; Ohtani S; Sato N; Saji S; Takano T; Tokunaga E; Nakamura S; Hasegawa Y; Hattori M; Fujisawa T; Morita S; Yamaguchi M; Yamashita H; Yamashita T; Yamamoto Y; Yotsumoto D; Toi M; Ohno S
Breast Cancer; 2020 May; 27(3):389-398. PubMed ID: 31811519
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment.
Linderholm B; Andersson J; Lindh B; Beckman L; Erlanson M; Edin K; Tavelin B; Grankvist K; Henriksson R
Eur J Cancer; 2004 Jan; 40(1):33-42. PubMed ID: 14687787
[TBL] [Abstract][Full Text] [Related]
18. Discordance in pathology report after central pathology review: Implications for breast cancer adjuvant treatment.
Orlando L; Viale G; Bria E; Lutrino ES; Sperduti I; Carbognin L; Schiavone P; Quaranta A; Fedele P; Caliolo C; Calvani N; Criscuolo M; Cinieri S
Breast; 2016 Dec; 30():151-155. PubMed ID: 27750105
[TBL] [Abstract][Full Text] [Related]
19. Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression.
Balduzzi A; Bagnardi V; Rotmensz N; Dellapasqua S; Montagna E; Cardillo A; Viale G; Veronesi P; Intra M; Luini A; Pruneri G; Mastropasqua G; Goldhirsch A; Colleoni M
Clin Breast Cancer; 2014 Aug; 14(4):258-64. PubMed ID: 24325948
[TBL] [Abstract][Full Text] [Related]
20. The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.
Sánchez-Muñoz A; Plata-Fernández YM; Fernández M; Jaén-Morago A; Fernández-Navarro M; de la Torre-Cabrera C; Ramirez-Tortosa C; Lomas-Garrido M; Llácer C; Navarro-Perez V; Alba-Conejo E; Sánchez-Rovira P
Clin Breast Cancer; 2013 Apr; 13(2):146-52. PubMed ID: 23318089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
